This article describes the automation of an in vitro cell-based fusion assay for the identification of novel inhibitors of receptor mediated HIV-1 entry. The assay utilises two stable cell lines: one expressing CD4, CCR5 and an LTR-promoter/βgalactosidase reporter construct, and the other expressing gp160 and tat. Accumulation of β-galactosidase can only occur following fusion of these two cell lines via the gp160 and receptor mediators, as this event facilitates the transfer of the tat transcription factor between the two cell types. Although similar cell fusion systems have been described previously, they have not met the requirements for HTS due to complexity, throughput and reagent cost. The assay described in this article provides significant advantage, as (a) no transfection / infection events are required prior to the assay, reducing the potential for variability, (b) cells are mixed in solution, enhancing fusion efficiency compared to adherent cells, (c) miniaturisation to low volume enables screening in 384-well plates; and (d) online cell dispensing facilitates automated screening. This assay has been employed to screen~650,000 compounds in a singleton format. The data demonstrate that the assay is robust, with a Z' consistently above 0.6, which compares favourably with less complex biochemical assays. (Journal of Biomolecular Screening 2004:516-524) 
INTRODUCTION
T HERE ARE A NUMBER OF ANTIRETROVIRAL DRUGS currently being employed for the treatment of infection with HIV. These are used in combination, defined as highly active antiretroviral therapy (HAART), and include nucleoside reverse transcriptase inhibitors (NRTIs), nonnucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PI). These proteins have been of high interest as targets for HIV therapy as they play an essential role in the viral replication process and are readily amenable to high-throughput screening (HTS) using in vitro biochemical techniques. [1] [2] [3] However, the majority of these agents have demonstrated adverse drug effects or have been limited in their use by the complexity of the HAART regimen and by the emergence of mutated virus strains that display drug resistance. [4] [5] [6] [7] To identify alternative medicines that provide significant advantage compared to existing therapies, there is a need to consider investigating different mechanisms to inhibit the viral life cycle, for example, the process of receptor-mediated viral entry.
The mechanism of HIV entry into its target cells involves a complex series of binding events. Glycoproteins of the virus envelope, gp120 and gp41, and cell surface receptors of the host cell, such as CD4 and CCR5 or CXCR4, are required for the process. [8] [9] [10] Binding of the virus to the host cell occurs via interaction between host cell CD4 and viral gp120 proteins. Subsequent conformational changes in gp120 and gp41 then promote high-affinity binding to CCR5 or CXCR4, which then facilitates fusion of the virus and host cell membranes.
Previously, screening methods aimed at exploiting this area have focused on the use of labeled ligands and/or binding assays with isolated glycoprotein molecules. Although there has been some success with this strategy in the identification of inhibitors, [11] [12] [13] [14] [15] assays that more accurately reflect the complexity of the biological system have a potential advantage to maximize the probability of identifying a novel small molecule that is effective as an anti-HIV agent. 19, 20 The process of receptor-mediated viral fusion can be mimicked using cell lines expressing either viral glycoproteins or host cell re-ceptors. Cell fusion assays utilizing these 2 types of cell line have previously been described for the characterization of HIV infection, as well as evaluation of potential blockers. [18] [19] [20] However, the challenge to the pharmaceutical industry has been to utilize such a complex assay system for a fully automated high-throughput screen.
Assay methods such as those described by Pine et al. 20 in which cell fusion is detected through the transfer of dye between 2 cell populations require the use of wash and centrifugation steps and are, therefore, not readily adaptable to an automated screening platform. Other groups, for example, Hong et al. 19 have also highlighted the difficulties in using transiently transfected cells and/or cells cultured in monolayer when establishing higher throughput fusion assays. For these reasons, reagent design and the early evaluation of automation were important considerations in the development of the assay protocol described in this article.
The system employed in this study consists of 1 cell line expressing gp160 (comprising viral glycoproteins gp120 and gp41) and tat (viral transcription regulator) and another cell line expressing the CD4 receptor, CCR5 co-receptor, and a β-galactosidase reporter. Fusion of the 2 cell lines results in the accumulation of βgalactosidase, which can subsequently be quantified via detection of a fluorescent product. Therefore, this in vitro system can be utilized to quantitatively measure fusion events in a homogeneous format.
Gene transcription assays, using reporters such as luciferase or β-lactamase, and cell-based assays that measure changes in intracellular calcium levels, have frequently been employed in HTS in recent years. These protocols are often compatible with preparation of cell plates off-line of the robotic system, prior to initiation of the assay. However, in this cell-cell fusion system, it is essential that compounds are added at the time of cell mixing, or inhibition of the fusion event will not be detected. Therefore, to ensure the successful automation of such an assay, it was necessary to dispense the cells online and consider the subsequent hurdles of ensuring that the sterility and viability of the cell lines were maintained. This report describes the development and application of a 384well fusion assay and its full automation using standard robotic equipment. The assay displays quality measures comparable with less complex biochemical assays and has been successfully employed to identify small molecule inhibitors of the HIV/host cell fusion process.
MATERIALS AND METHODS

Cell lines
The CHO-Tat10 cell line was developed in collaboration with Mark Goldsmith, PhD (Gladstone Institute, San Francisco, CA). This is a tat-expressing clone from the CHO JRR17.1 cell line that expresses gp160 (JRFL) and has been transfected with pTat puro plasmid. The cells are maintained in RPMI1640 medium supple-mented with 10% FCS, 2 mM L-glutamine, and with 500 µg/mL G418, 500 µg/ml hygromycin, and 12 µg/ml puromycin.
The HeLa-P4 cell line was licensed from Ned Landau, PhD (Aaron Diamond AIDS Research Centre, New York, New York). This cell line expresses CCR5/CD4 and has been transfected with HIV-1 LTR-β-galactosidase. The cells are maintained in DMEM supplemented with 10% FCS, 2 mM L-glutamine, and 1 µg/mL puromycin.
Reagents
The FluorAce™ β-galactosidase kit was purchased from Bio-Rad (Hemel Hempstead, UK). 384-well, black, clear bottom, tissue culture-treated plates were obtained from Greiner (Stonehouse, UK). Cell culture media, with the exception of serum, was obtained from Gibco (Paisley, UK). Fetal calf serum was obtained from PAA (Yeovil, UK). All other reagents were purchased from Sigma (Poole, UK).
Fusion assay
CHO-Tat10 and HeLa-P4 cells were grown in 225 cm 2 flasks or roller bottles to confluence. Cells were washed twice with PBS and harvested using Trypsin EDTA. Cells were pooled into 2 separate 1-liter sterile spinner flasks, 1 for each cell line. A cell count was performed, and the cell suspension was diluted in medium (DMEM with 2 mM L-glutamine and 2% FCS for HeLa-P4 or RPMI1640 with 2 mM L-glutamine and 2% FCS for CHO-Tat10) to give a suspension at 6.6 × 10 5 cells per mL. The spinner flasks were connected to a 5% CO 2 gas supply to maintain pH and stirred at 30 rpm at room temperature during dispensing. Fifteen microliters of CHO-Tat10 and 15 µL of HeLa-P4 were added sequentially to a sterile tissue culture-treated 384-well plate containing 10 µL compound/control solution (360 wells of test compound and 8 wells each of a maximum [no inhibitor], minimum [saturating concentration of fusion inhibitor], and standard [an IC 50 concentration of a fusion inhibitor] controls). Plates were lidded and incubated at 37°C and 5% CO 2 in a humidified (Cytomat) incubator. After 20 h, 20 µL of reaction buffer (13.4% Glycerol, 1.3% Triton-X100, 0.34 M Tris [pH7.8], 200 µM 4-methylumbelliferyl-galactoside (MUG), 0.028% β-mercapto-ethanol, 33% Bio-Rad 1 × reaction buffer) was added to each well. Plates were incubated at 25°C for a further 2 h, during which time cell lysis occurred, and then 10 µL of Bio-Rad 10 × stop buffer was added to each well. The fluorescent signal was detected, after a further 45-min incubation, using a Tecan Spectrafluor Plus (Tecan) (λ ex = 360 nm, λ em = 460 nm; bottom reading; 3 flashes; gain = 50-60).
Robotic system
For automated screening, the assay was adapted to run on a Robolab 9600 (Robocon, Vienna, Austria). Cells were maintained in spinner flasks and dispensed with 2 Multidrops (Labsystems,
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Helsinki, Finland). Compounds were transferred to the assay plates with a CyBiWell (CyBio, Jena, Germany) with 384-tip head (10 µL tips) and controls added using a Tecan Genesis (Tecan, Salzburg, Austria). After dispensing and compound addition, cells were kept at 37°C in a Heraeus Cytomat (Kendro, Bishops Stortford, UK). For β-galactosidase quantification lysis buffer, substrate and stop reagent were added with the Robolab Reagent addition stations. Plates were read on a Tecan Spectrafluor Plus (Tecan).
Data analysis
To determine the effects of test compounds in the fusion assay, data were normalized to the controls on a per plate basis, and percentage activity values were calculated. Compounds tested at 10 µM were considered "active" when they demonstrated > 30% inhibition compared to controls (defined above). For IC 50 determinations, data were normalized to controls on a per plate basis and the percentage activity at each dose was calculated. Data were then plotted against the corresponding dose and fitted using a 4-parameter logistic equation. Both sets of analyses were carried out using a software package developed, through contract, specifically for Pfizer.
RESULTS AND DISCUSSION
Screen development
The cell-cell fusion system employed in this study requires the mixture of 2 stable cell lines expressing different components of the virus and host cell proteins along with tat (viral transcriptional transactivator) and a tat-regulated reporter gene, β-galactosidase. More specifically, the first cell line (HeLa-P4) stably expresses the CD4 receptor, CCR5 co-receptor, and a β-galactosidase reporter under the control of the long terminal repeat (LTR) promoter. The second cell line (CHO-Tat 10) stably expresses gp160 (equivalent to viral glycoproteins gp120 and gp41) and tat. Fusion of the 2 cell lines, following their mixture, facilitates tat transfer between cells and enables subsequent binding to the LTR, resulting in the accumulation of β-galactosidase enzyme. This enzyme activity is then quantified via detection of a fluorescent product derived from the β-galactosidase substrate MUG. This process is schematically represented in Figure 1 .
To validate the approach, a fusion assay was carried out in 384well plates where syncytia formation and β-galactosidase production were confirmed by visual microscopic assessment (Fig. 2) . These studies indicated that syncytia were formed when cells were mixed, compared to controls with either HeLa-P4 or CHO-Tat10 cells alone. Having qualitatively confirmed that the fusion of the 2 cell populations could be observed, quantitative studies to determine the optimum cell ratio and incubation time were then performed using the β-galactosidase reporter (Fig. 3A, B ). Data demonstrated that the optimal cell ratio was a 1:1 mixture of CHO-Tat10 and HeLa P4 and that initial β-galactosidase activity could be detected after 5 h, with activity continuing to rise until 20 h, after which the signal stabilized. Although a 5-h assay would maximize throughput and minimize the potential of compound artifacts, the 20-h incubation was employed in further studies because syncytia formation was optimal after 16 h and the signal at 5 h was not as viable for robust screening as later time points.
To establish any fully automated assay for HTS, consideration is given to the impact of liquid handling steps and dispensing volumes on efficiency of robotic handling. However, for this cellbased assay, it was especially important to consider the handling of live cells in an automated environment, as this was likely to have a significant impact on the stability and reproducibility of the assay. Therefore, preliminary studies addressing the cell tolerance to compounds and cell dispensing parameters were carried out to assess the feasibility of achieving an automated assay.
As compounds are routinely prepared in DMSO, the effects of DMSO on the cell viability and signal generation were examined. The data indicated that the assay signal, and thus the viability of the cells, was comparable with DMSO concentrations ranging from 0% to 1% (data not shown). This confirmed that the assay was suitable for use in a primary screen (10 µM final concentration of test compound) and follow-up dose response studies (highest compound concentration 25 µM) where levels of DMSO would be either 0.25% or 0.625%, respectively. The dynamics of the fusion process dictate that the 2 cell lines are mixed at the time of compound addition to ensure that cells are exposed to potential inhibitors before cell-cell interactions have occurred. For full automation, it was therefore necessary to dispense cells online. The overall number of cells per well was likely to influence the signal produced, due to the consequent alterations in total β-galactosidase levels. In addition, efficient cell fusion was achieved at a 1:1 ratio of CHO-Tat10 to HeLa-P4 cells (Fig. 3B ). Therefore, it was critical to ensure that the cells remained at a constant density for prolonged periods during the robotic schedule prior to addition to the assay plate. As both CHO and HeLa cells proliferate in suspension when maintained at 37°C, the possibility of dispensing the HeLa-P4 and CHO-Tat10 cell lines from suspen-sion cultures maintained at ambient temperature (25°C) was investigated by evaluating the impact of this procedure on the efficiency of their fusion (data not shown). Controls using either HeLa-P4 or CHO-Tat10 cells alone indicated that no βgalactosidase was produced and very low fluorescence values were obtained. This eliminated the need to subtract background signals from the data and suggested that tightly controlled gene expression was achieved with the LTR promoter. Cells also remained viable, as indicated by the increase in β-galactosidase upon fusion. Furthermore, as the total signals obtained using cells maintained for either 6 h or 48 h at ambient temperature were approximately equivalent, growth was sufficiently restricted under these conditions for an automated schedule. Further studies to optimize the assay for full HTS considered aspects of the β-galactosidase detection that followed the cell fusion event. A variety of reagents are available for the detection of β-galactosidase, but this study focused on the MUG substrate because although chemiluminescent reagents were potentially less susceptible to compound interference, they tended to be more expensive. In addition, early evaluation with the MUG substrate indicated that the potential impact of false positives due to compound interference was minimal (data not shown). Therefore, emphasis was placed on the stability and addition of the MUG βgalactosidase substrate at room temperature, which was beneficial in terms of robotic handling, but, importantly, minimized variability occurring as a result of cellular responses to frequent changes in temperature.
Detection of -galactosidase activity
The stability of the β-galactosidase reagent was assessed to minimize the need for cooled reagent additions during a fully automated robotic screen. Data indicated that there was no significant difference between the use of substrate at 4°C or ambient temperature over a 24-h period (data not shown). Furthermore, as the fluorescent product was likely to be sensitive to variability in pH (fluorescent intensity increased with high pH), the effects of different incubation times following the addition of stop reagent were also monitored. Although without incubation the data were variable between the wells in a plate, after 45 min the signal was found to be consistent (data not shown). This observation is likely to be attributable to a combination of the time taken for the solutions to mix and for the assay to reach pH equilibrium, following addition of the stop buffer to wells that contain buffered cell growth medium.
Because the rate of substrate conversion was expected to be influenced by cell concentration, studies to determine the time course for β-galactosidase detection at room temperature were performed at a range of cell concentrations. Following substrate addition, assay plates were incubated at ambient temperature and substrate conversion rates were determined by monitoring the increase in fluorescence over a 24-h period (Figure 4) . As expected, cell number influenced substrate conversion rates and acceptable conversion rates were achieved at concentrations of between 0.625 and 2.5 × 10 4 cells/well for each cell line. At these cell concentrations, a robust fluorescent signal was achieved after 2 h incubation, and at this time point the rate of increase in fluorescence remained within the linear part of the substrate conversion curve. Based on these studies, a seeding density of 1 × 10 4 cells per well for each cell line and an incubation time of 2 h were selected for the βgalactosidase assay. This provided an appropriate balance between maximizing the signal, minimizing the number of cells required for the HTS, and minimizing the impact of the additional incubation time on the 20 h already required for the assay.
Considerations for automated dispensing of cells and compounds
Cell-based assays that require long incubation times following compound addition are susceptible to the loss of data resulting from the effects of microbial contamination. Although it is impractical to handle the large number of compounds required for screening in a sterile environment, the likelihood of microbial contamina-tion was minimized by ensuring that liquid handling equipment was sterilized daily using 70% ethanol in water, tips were washed in sterile water between compound additions, and test compounds were prepared using sterile buffers.
To dispense cells on the RoboCon™ system, it was also necessary to adapt the Bellco "spinner flasks" to maximize the efficiency and facilitate aseptic withdrawal of the cells via the Multidrop dispensers, by fitting one arm of the vessel with a modified lid and by modifying the stirring blades, respectively (Fig. 5 ). Because both cell lines were suspended in media based on sodium bicarbonate buffer, a constant pH in the spinner flasks was maintained by supplying a 5% CO 2 /95% air mixture to the headspace of each flask. To prevent cells held in the silicone tubing of the Multidrop from settling or being affected by changes in pH, they were returned to the flask between dispense runs. To avoid foaming of the cellgrowth medium during this procedure, a very thin film of vacuum grease was applied to the outer surface of the tips on the Multidrop head. To minimize microbial contamination, the procedure was optimized to ensure that very little or no air was drawn back into the flask.
Assay automation and validation for HTS
Experiments monitoring the maximum and minimum assay signals over time indicated that the cells remained viable on the system for up to 24 h, with the maximum signal dropping by only 10% to 20% over this time period (Fig. 6A ). During this time, the Z′ value was found to be consistently above 0.6, indicating that the assay was robust over this 24-h period. The effect of assay duration on the IC 50 values obtained for a CCR5 antagonist was also determined under the same assay conditions (Fig. 6B) . These results indicated that there was a gradual increase in potency of the compounds with time resulting in a 3-fold change in the IC 50 between cells utilized immediately and those used 24 h after loading on to the robot. One explanation for this observed shift in IC 50 is that, although the cells remained viable throughout the period of suspended growth at room temperature, the level of expression of one or more of the receptors involved in the fusion process was altered. Such a decline in surface receptor expression on a per-cell basis may result in the apparent increase in potency of inhibitors either by altering the kinetics of cell fusion resulting in a looser association between cells or by reducing the number of cell surface receptors not actively involved in the fusion process. Published work supporting this theory demonstrated that the apparent potency of a peptide inhibitor (T20) and the t 1/2 of the fusion event were increased when levels of CCR5 were reduced. 21 However, to minimize this effect during screening, the cells were prepared and then dispensed after an 8-h delay, during which time there was only a 2-fold variation ( Fig. 6B; 8 -24 h). Under these conditions, the IC 50 observed was comparable to that obtained in a MIP-1β/CCR5 radioligand binding assay (data not shown), supporting the validity of using cells during this time period.
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Screen validation
The above data confirmed that the assay could be optimized to a 384-well format and automated on the RoboCon™ system. However, to ensure that the screen would detect activity of novel compounds of the desired potency (≤ 5µM), further validation was carried out. Test compounds are routinely screened at a final concentration of 10 µM, and compounds of 5 µM activity would be expected to produce~66% inhibition in the assay (assuming Hill slope = 1) at this concentration. Therefore, to determine an appropriate threshold for the identification of "actives" versus "inactives," data were generated to determine the normal distribution around 0% inhibition and 66% inhibition ( Fig. 7) . To determine activity at 0% inhibition, a random selection of compounds representative of the screening file, which will be predominantly inactive, was tested (n = 2). To mimic activity of a 5 µM active, a known inhibitor was tested at the appropriate concentration to provide 66% inhibition. Based on these data, a threshold was set, which captured > 97% of the data for the 66% population, without capturing a significant proportion of the 0% population. This ensured that there was a > 97% probability of detecting compounds with ≤ 5 µM potency, while incurring a minimal false positive rate. For this screen, a threshold of 30% inhibition was employed to define actives. Having selected a threshold of 30%, the data generated with the random compound selection was analyzed to determine if any actives with > 30% inhibition were identified. The average number of actives from the 2 data sets was then used to predict that a hit rate of 1.4% would be obtained. To estimate the repeat rate, the proportion of compounds active in both tests (considered as "true" actives) was calculated as a percentage of the total number of actives identified. The estimated repeat rate of 26% that was obtained for this screen is relatively low but is likely to be a direct consequence of the low cut-off employed and the inherent variability of low activity compounds (> 5 µM) as~90% of the compounds that failed to repeat had activity between 31% and 44% inhibition.
Analysis of HTS results
Using the assay as described above, approximately 650,000 compounds were tested at a concentration of 10 µM in a noncompressed format. To assess the quality of the screen, the Z′ factor was determined using the control wells on each plate. As shown in Figure 8A , the Z′ was ≥ 0.6 throughout the entire screen, with the majority falling between 0.8 and 0.9. This compares well with other automated cell-based assays and biochemical assays carried out by this group. 22, 23 Furthermore, when the frequency distribution was plotted for the percent inhibition data of each compound, a normal distribution around zero was observed (Fig. 8B) . These data indicated that the screen was robust and that it had performed as predicted based on the validation experiments (see above).
A total of 9927 primary actives were detected in the primary screen, of which 3004 were confirmed to have activity upon retest at 10 µM. This represented a primary active rate of 1.5% and a repeat rate of~31%. The hit rate and repeat rate observed for this screen were similar to those predicted by the pre-HTS validation studies (see above). This suggested that the experiments described above to validate the HTS were appropriate and that no unexpected artifacts had arisen during the screen. In addition, although direct comparison cannot be made due to the differences in target family and the specific activity threshold selected, it is also encouraging to note that the hit rate observed for this screen was not significantly different from other assays performed within the group. 22 This  FIG. 7 . Distribution of compound effects. A random subset of the compound file and a known inhibitor of fusion were tested in the automated fusion assay to determine the cutoff for the high-throughput screening. The data represented are a frequency distribution for different percent inhibition (0% and~66%) obtained in the assay. Based on these data, a threshold of 30% inhibition was employed to identify actives from the screen. This ensured that there was a > 97% probability of detecting compounds with ≤ 5 µM potency, while maintaining a minimal false-positive rate.
suggests that measures to minimize contamination were successful and that no significant compound artifacts were observed as a consequence of the prolonged incubation required for this assay.
Following a review of the structures, 1256 compounds were selected from the 3004 confirmed actives at 10 µM for IC 50 followup. As the primary assay used in this HTS mimics the complexity of the biological process, the activity of compounds detected could be attributed to a number of possible mechanisms. These include nonspecific cytotoxic effects, β-galactosidase inhibition, tat inhibition, CD4/gp120 or CCR5 blockade, or an unprecedented mechanism. Assessment of the selected 1256 HTS hits indicated that only 6% of these active compounds were cytotoxic, further highlighting that the 20-h incubation time required to detect optimal fusion did not result in significant problems. The remaining chemical series are being further evaluated to determine their mechanism of action; however, it is encouraging to note that preliminary evaluation of one of the chemical series in an HIV infection assay confirmed activity (data not shown).
CONCLUSION
The assay described in this report utilizes 2 stable cell lines mixed in suspension in a 384-well protocol that requires no wash or centrifugation steps. With careful consideration to cell viability, the issues that may have arisen with online cell dispensing have been overcome to achieve a fully automated assay. This fully automated cell fusion assay was employed in a high-throughput screen of~650,000 compounds. Despite the long incubation times required for the fusion process, a throughput of 40,000 data points per day was achieved, which is considerably higher than that achievable with the previously described methods. Moreover, the quality of the data obtained during the development and validation of the assay compared favorably with more traditional cell-based and biochemical assays. The good Z′ values (> 0.6) and apparent lack of compound interference may be in part due to the tightly controlled gene expression achieved with the LTR promoter and the relatively high levels of tat-induced gene expression. This assay clearly represents a significant advantage over previously described methods. Data indicate that the screen had performed as predicted with a Z′ consistently above 0.6. The Z′ was calculated from the control wells on each plate used in the screen. Eight maximum controls and 8 minimum controls are included per plate, with 10 plates per "experiment" and 12 "experiments" per day. (B) Frequency distribution of inhibition values. The data represented are frequency versus percent inhibition. The data obtained display a normal distribution around zero, reflecting the fact that the majority of compounds were inactive. This highlights that the assay had performed as predicted, with minimal artifacts due to compound interference.
